GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » Growth Rank

AQSZF (Aequus Pharmaceuticals) Growth Rank : 0 (As of Mar. 02, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Growth Rank?

Aequus Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Aequus Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals Headlines

From GuruFocus

Aequus Reports Third Quarter 2022 Financial Highlights

By GlobeNewswire GlobeNewswire 11-30-2022

Aequus Grants Stock Options

By sperokesalga sperokesalga 04-19-2023

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 07-06-2022

Aequus Announces Zimed PF Website Launch

By Marketwired 08-22-2023

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 07-03-2022

Aequus Provides General Update and Fiscal 2022 Financial Results

By GlobeNewswire GlobeNewswire 05-02-2023